Skip to content

DERM NMSC Validation Study

Effectiveness of an Image Analysing Algorithm (DERM) to Diagnose Non-melanoma Skin Cancer (NMSC) and Benign Skin Lesions Compared to Gold Standard Clinical and Histological Diagnosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04116983
Enrollment
572
Registered
2019-10-07
Start date
2020-06-26
Completion date
2022-03-16
Last updated
2022-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-melanoma Skin Cancer

Brief summary

This study aims to establish the effectiveness of an Artificial Intelligence (AI) algorithm (DERM) to determine the presence of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) and frequently observed benign conditions, when used to analyse images of skin lesions taken by commonly available smart phone cameras.

Detailed description

DERM, an Artificial Intelligence (AI)-based diagnosis support tool, has been shown to be able to accurately identify Non-melanoma skin cancers (NMSC) and other conditions from historical images of suspicious skin lesions (moles). This study aims to establish how well DERM determines the presence of these conditions in images of skin lesions collected in a clinical setting. Suspicious skin lesions that are due to be assessed by a dermatologist and a patch of healthy skin will be photographed using three commonly available smart phone cameras with a specific lens attachment. The images will be analysed by DERM, and the results compared to the clinician's diagnosis (all lesions) and histologically-conformed diagnosis (any lesion that is biopsied).

Interventions

An AI-based diagnosis support tool

Sponsors

Innovate UK
CollaboratorOTHER_GOV
Skin Analytics Limited
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participant is willing and able to give informed consent for participation in the study, * Male or Female, aged 18 years or above, * Have at least suspicious skin lesion which is suitable for photographing (\<15mm, not located on an anatomical site inappropriate to photograph (genitalia, hair-bearing areas, under nails), not previously biopsied, not located in an area of visible scarring or tattooing), * In the Investigator's opinion, able and willing to comply with all study requirements.

Exclusion criteria

* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
AUROC of DERM performance when analysing images of biopsied lesionsStudy completionArea Under the Receiver Operating Characteristic Curve (AUROC) of the DERM result of biopsied lesions, using histopathological-confirmed diagnosis as gold standard

Secondary

MeasureTime frameDescription
The sensitivity of DERM when used to assess non-biopsied lesionsStudy completion: on average 2 daysThe sensitivity of DERM when used to assess non-biopsied lesions
Concordance of clinician assessment with histologically confirmed diagnosisStudy completion: on average 2 daysConcordance of clinician assessment with histologically confirmed diagnosis
The concordance of DERM result generated using images from each cameraStudy completion: on average 2 daysThe concordance of DERM result generated using images from each camera
The proportion of skin lesions with 3 images that can be analysed by DERM;Study completion: on average 2 daysThe proportion of skin lesions with 3 images that can be analysed by DERM;
The proportion of skin lesions with at least 1 readable image that can be analysed by DERMStudy completion: on average 2 daysThe proportion of skin lesions with at least 1 readable image that can be analysed by DERM
AUROC of DERM performance when analysing images of non-biopsied lesionsStudy completion: on average 2 daysArea Under the Receiver Operating Characteristic Curve (AUROC) of the DERM result of biopsied lesions, using clinical diagnosis as gold standard
The sensitivity of DERM when used to assess biopsied lesionsStudy completion: on average 2 daysThe sensitivity of DERM when used to assess biopsied lesions
The specificity of DERM when used to assess biopsied lesionsStudy completion: on average 2 daysThe specificity of DERM when used to assess biopsied lesions
The false positive rate of DERM when used to assess biopsied lesionsStudy completion: on average 2 daysThe false positive rate of DERM when used to assess biopsied lesions
The false negative rate of DERM when used to assess biopsied lesionsStudy completion: on average 2 daysThe false negative rate of DERM when used to assess biopsied lesions
The positive predictive value of DERM when used to assess biopsied lesionsStudy completion: on average 2 daysThe positive predictive value of DERM when used to assess biopsied lesions
The negative predictive value of DERM when used to assess biopsied lesionsStudy completion: on average 2 daysThe negative predictive value of DERM when used to assess biopsied lesions
The specificity of DERM when used to assess non-biopsied lesionsStudy completion: on average 2 daysThe specificity of DERM when used to assess non-biopsied lesions
The false positive rate of DERM when used to assess non-biopsied lesionsStudy completion: on average 2 daysThe false positive rate of DERM when used to assess non-biopsied lesions
The false negative rate of DERM when used to assess non-biopsied lesionsStudy completion: on average 2 daysThe false negative rate of DERM when used to assess non-biopsied lesions
The positive predictive value of DERM when used to assess non-biopsied lesionsStudy completion: on average 2 daysThe positive predictive value of DERM when used to assess non-biopsied lesions
The negative predictive value of DERM when used to assess non-biopsied lesionsStudy completion: on average 2 daysThe negative predictive value of DERM when used to assess non-biopsied lesions

Other

MeasureTime frameDescription
The impact of image variables on the diagnostic accuracy of DERM assessmentStudy completion: on average 2 daysThe impact of image variables (such as macro and dermoscopic images) on the diagnostic accuracy of DERM assessment
DERM performance (AUROC) when macro images are used both to train the algorithm and as test imagesStudy completion: on average 2 daysExploration of whether macro images can be used as part of DERM's assessment
Impact of lesion characteristics on the DERM and clinician assessmentStudy completion: on average 2 daysThe impact of lesions characteristic (such as growth over last 6 months, stage and sub-type) on the diagnostic accuracy of DERM and clinician assessment
Impact of patient characteristics on the DERM and clinician assessmentStudy completion: on average 2 daysThe impact of patient characteristics (such as sex, age, location of lesion, total body lesion count, Fitzpatrick skin type, past medical history of skin cancer) on the diagnostic accuracy of DERM and clinician assessment;

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026